A Critical Review on the Structural Health Monitoring Methods of the Composite Wind Turbine Blades

With increasing turbine size, monitoring of blades becomes increasingly im-portant, in order to prevent catastrophic damages and unnecessary mainte-nance, minimize the downtime and labor cost and improving the safety is-sues and reliability. The present work provides a review and classification of various structural health monitoring (SHM) methods as strain measurement utilizing optical fiber sensors and Fiber Bragg Gratings (FBG’s), active/ pas-sive acoustic emission method, vibration‒based method, thermal imaging method and ultrasonic methods, based on the recent investigations and prom-ising novel techniques. Since accuracy, comprehensiveness and cost-effectiveness are the fundamental parameters in selecting the SHM method, a systematically summarized investigation encompassing methods capabilities/ limitations and sensors types, is needed. Furthermore, the damages which are included in the present work are fiber breakage, matrix cracking, delamina-tion, fiber debonding, crack opening at leading/ trailing edge and ice accre-tion. Taking into account the types of the sensors relevant to different SHM methods, the advantages/ capabilities and disadvantages/ limitations of repre-sented methods are nominated and analyzed

Interleukin-1 Blockade: An Update on Emerging Indications

Interleukin (IL)-1 is a pro-inflammatory cytokine that induces local and systemic inflammation aimed to eliminate microorganisms and tissue damage. However, an increasing number of clinical conditions have been identified in which IL-1 production is considered inappropriate and IL-1 is part of the disease etiology. In autoinflammatory diseases, gout, Schnitzler’s syndrome, and adult-onset Still’s disease, high levels of inappropriate IL-1 production have been shown to be a key process in the etiology of the disease. In these conditions, blocking IL-1 has proven very effective in clinical studies. In other diseases, IL-1 has shown to be present in disease process but is not the central driving force of inflammation. In these conditions, including type 1 and 2 diabetes mellitus, acute coronary syndrome, amyotrophic lateral sclerosis, and several neoplastic diseases, the benefits of IL-1 blockade are minimal or absent